Basimglurant

Basimglurant emerged from a Roche medicinal-chemistry program that optimized a weakly active screening hit into a potent and selective mGlu5 negative allosteric modulator with favourable pharmacokinetics in rat and monkey; the same effort produced the long-half-life research tool CTEP ^[1]. In preclinical anxiety models basimglurant matched the efficacy of diazepam at 10 to 100 fold lower doses, supporting its move into psychiatric trials ^[1]. The compound was formulated as a once-daily modified-release tablet to provide steady central exposure.

In a phase 2b study of 333 adults with major depressive disorder and inadequate antidepressant response, adjunctive basimglurant did not separate from placebo on the clinician-rated Montgomery-Asberg Depression Rating Scale primary endpoint, but the 1.5 mg dose produced consistent improvements across patient-rated depression measures, response and remission rates, with dizziness the most common adverse event ^[2]. In the FragXis phase 2 trial in adolescents and adults with fragile X syndrome, basimglurant did not demonstrate significant benefit on the primary behavioural endpoint, mirroring the broader disappointment of mGlu5-targeted fragile X programs ^[3]. The divergence between clinician-rated and patient-rated depression outcomes has kept interest alive in the mGlu5 mechanism for mood disorders.

In the phase 2b depression trial basimglurant was generally well tolerated, with dizziness the most frequent adverse event, usually transient and mild in intensity. The favourable preclinical drug-metabolism and safety profile was a selling point of the molecule relative to earlier mGlu5 ligands. As an investigational agent it carries no approved indication and its long-term safety in humans is not established.

Basimglurant was discovered at Roche and reported in 2015 as a promising mGlu5 negative allosteric modulator for psychiatric disease, entering phase 2 development for depression and fragile X syndrome. The depression program, reported in 2016, generated a nuanced result in which patient-reported outcomes outperformed clinician ratings. The fragile X FragXis program, like other mGlu5 fragile X efforts, failed to confirm benefit, and active development did not progress to registration.

Basimglurant is widely cited as a benchmark clinical mGlu5 negative allosteric modulator and as evidence that mGlu5 blockade can produce antidepressant-like signals, particularly on subjective measures. Its trials are frequently invoked in debates over clinician-rated versus patient-rated endpoints in psychiatry. Among researchers it is respected for its clean pharmacology, and its sibling tool compound CTEP is a mainstay of chronic rodent mGlu5 studies.